All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Is CD47 a good target for immunotherapy in lymphoma?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Steven Horwitz, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Is CD47 a good target for immunotherapy in lymphoma?
Is CD47 a good target for immunotherapy in lymphoma?
Horwitz discusses the unmet need for immunotherapy in lymphoma, and whether targeting CD47 could be a viable treatment strategy. He also gives an overview of early safety and efficacy data and outlines future research for CD47 targeting.
Dr. Horwitz has consulted, received honorarium from, or participated in advisory boards for; Acrotech Biopharma, C4 Therapeutics, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Seattle Genetics, Takeda, Trillium Therapeutics, and Vividion Therapeutics.
Dr. Horwitz has received research support for clinical trials from ADC Therapeutics, Affimed, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium /Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, and Verastem.